PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Eligible patients will receive single-agent PTT-936 administered per orally (PO).

Eligible patients will receive combination treatment consisting of PTT-936 administered PO in combination with a Standard of Care (SOC) regimen of an anti-PD-1/L1 agent administered intravenously (IV).